Search
GlaxoSmithKline Acquires Another Drug from D1 Medical for Up to $750 Million
1 day ago /
Read about 0 minute
Author：小编
GlaxoSmithKline will purchase an experimental blood cancer drug from Chinese biotechnology company D1 Medical for up to $750 million to enrich its oncology treatment portfolio. The drug will be tested for the treatment of multiple myeloma, with early-stage clinical trials expected to commence next year.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
